Assembly Biosciences, Inc. (ASMB) vs NeoGenomics, Inc. (NEO)

A side-by-side comparison of Assembly Biosciences, Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ASMB vs NEO

growth of $100 · dividends reinvested · last 10y
ASMB -73.7% (-12.5%/yr)NEO +134.5% (+8.9%/yr)NEO compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020182020202220242026$26$234
ASMB NEO

ASMB vs NEO: by the numbers

  • •ASMB is the larger company ($435M vs $429M market cap).
  • •Both run net losses; ASMB's is the smaller (-0.06% vs -6.77% net margin).
  • •NEO grew revenue faster over the past five years (9.41% vs -1.78% CAGR).

Metrics side by side

Valuation

MetricASMBNEO
P/E ratio39.95N/A
Forward P/EN/A91.28
P/S ratio5.820.56
P/B ratio1.420.55

Profitability

MetricASMBNEO
Gross margin99.82%42.92%
Operating margin-11.75%-8.63%
Net margin-0.06%-6.77%
ROE-0.01%-6.60%
ROIC-2.86%-5.29%

Growth (annualized)

MetricASMBNEO
Revenue CAGR (5Y)-1.78%9.41%
Total return CAGR (5Y)-10.66%-15.14%

Frequently asked

Which has grown faster, ASMB or NEO?
Over the past five years, NEO grew revenue faster — ASMB at a -1.78% CAGR versus NEO at 9.41%.
How have ASMB and NEO total returns compared?
Over the past 10 years, ASMB delivered -13.41% and NEO delivered 8.90% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.